Gilead Sciences Inc.'s measured launch of the chimeric antigen receptor T-cell (CAR-T) therapy Yescarta is proceeding as expected, with 28 cancer centers in the US now ready to provide the treatment and $7m in sales for the fourth quarter.
Gilead's CAR-T Therapy Yescarta Slowly Getting Off The Ground
Slow and steady approach to launch should position Yescarta well in the long run, Gilead maintains – the CAR-T therapy brought in $7m in its first month. But Gilead is still suffering from the decline in hepatitis C.
More from Earnings
More from Business
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
• By
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.